ClinicalTrials.Veeva

Menu

Bevacizumab Against Recurrent Retinal Detachment (BEARRD)

University of Wisconsin (UW) logo

University of Wisconsin (UW)

Status and phase

Completed
Phase 2

Conditions

Proliferative Vitreoretinopathy
Retinal Detachment

Treatments

Drug: Bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT02192970
A536070 (Other Identifier)
2014-0931
SMPH/OPHTHAL&VIS SCI (Other Identifier)

Details and patient eligibility

About

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Enrollment

101 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years
  • Eyes with rhegmatogenous retinal detachment

Exclusion criteria

  • Presence of PVR
  • Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
  • Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
  • Secondary retinal detachment repair
  • Use of silicone oil as tamponade agent
  • Patients less than 18 years of age
  • Pregnancy
  • Known allergy or contraindication to intravitreal bevacizumab

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

101 participants in 2 patient groups

Bevacizumab
Experimental group
Description:
Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
Treatment:
Drug: Bevacizumab
Chart review
No Intervention group
Description:
Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems